What Researchers Did
South Korean researchers enrolled 1,005 hospitalized COVID-19 patients to determine whether pre-existing liver disease, particularly cirrhosis, worsened disease severity and mortality.
What They Found
Liver cirrhosis was present in 1.4% of patients but was significantly more common in those with severe pneumonia than mild disease (4.5% vs 0.9%). Patients with cirrhosis had higher rates of ICU admission, acute kidney injury, septic shock, and death; the overall survival rate was significantly lower in the cirrhosis group. Cirrhosis was an independent predictor of severe disease (OR 4.52) and death (HR 2.86).
What This Means for Canadian Patients
Canadian patients with liver cirrhosis who contract respiratory infections, including COVID-19, face substantially higher risk of severe complications. This reinforces the importance of early aggressive treatment and close monitoring for this vulnerable group.
Canadian Relevance
No direct Canadian connection identified. Note: this study is listed in the HBOT research database likely due to incidental HBOT MeSH tagging, not because HBOT was used as a treatment.
Study Limitations
This was a multi-centre observational study in South Korea; results may not translate directly to Canadian populations with different cirrhosis etiologies and healthcare settings.